In the last few years more and more drugs, such as TRK, ALK, checkpoint, and BRAF, as well as FGFR, inhibitors have been or are being evaluated in basket clinical trials, with some of them already formally approved as tumor agnostic therapies [24]. This evidence concerns the gene ALK and neoplasm.